Mycosis Fungoides

This trial is testing allogeneic stem cell transplant (from a donor) for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing Low-dose total-skin electron-beam therapy for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.

This trial is testing Durvalumab for patients with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial is available at 4 locations in the United States. The trial is currently recruiting patients.

This trial is testing Extracorporeal Photopheresis for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 3 locations in the United States. The trial is currently recruiting patients.

This trial is testing the combination of pembrolizumab (anti-PD-1) and mogamulizumab (anti-CCR4) for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Ruxolitinib for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing tofacitinib 2% cream applied to the skin for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing a hypomethylating agent (azacitidine or decitabine) based regimen for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing PTX-100 for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 6 locations in the United States. The trial is currently recruiting patients.

This trial is testing brentuximab vedotin for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 8 locations in the United States. The trial is currently recruiting patients.

This trial is testing Golidocitinib for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is not yet open for recruitment.

This trial is testing Mogamulizumab for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Riluzole for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Brentuximab vedotin for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing ultra-low-dose total skin electron beam radiation therapy for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Brentuximab Vedotin (Bv) for patients with anaplastic large cell lymphoma (ALCL) or cutaneous T-cell lymphoma (CTCL) at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing Aclarubicin for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing Benvitimod Cream for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing Mogamulizumab for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing CD7-directed CAR-T cell therapy for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing JAK1 Inhibitor for patients with cutaneous T-cell lymphoma (CTCL) or extranodal NK/T-cell lymphoma who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing CD5-directed CAR-T cell therapy for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing VG712 for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is not yet open for recruitment.

This trial is testing DT-7012 for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is an early Phase 1 trial, which means this is among the first tests of the treatment in patients, focusing on safety and dose. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This trial is testing CAR-T cell therapy (genetically modified immune cells) for patients with angioimmunoblastic T-cell lymphoma (AITL) or TFH lymphomas, anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (CTCL), enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, or subcutaneous panniculitis-like T-cell lymphoma whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This trial is testing Biopsy Procedure for patients with angioimmunoblastic T-cell lymphoma (AITL) or TFH lymphomas, anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (CTCL), or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 2 locations in the United States. The trial is currently recruiting patients.

This trial is testing Fenretinide for patients with angioimmunoblastic T-cell lymphoma (AITL) or TFH lymphomas or cutaneous T-cell lymphoma (CTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. This trial is available at 10 locations in the United States. The trial is currently recruiting patients.

This is a research study collecting clinical information and/or biological samples from patients with angioimmunoblastic T-cell lymphoma (AITL) or TFH lymphomas, anaplastic large cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL), enteropathy-associated T-cell lymphoma, extranodal NK/T-cell lymphoma, hepatosplenic T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), subcutaneous panniculitis-like T-cell lymphoma, or T-cell prolymphocytic leukemia at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial is available at 26 locations in the United States.

This study is developing and validating improved flow cytometry methods to better detect circulating tumor cells in patients with cutaneous T-cell lymphoma (CTCL) or enteropathy-associated T-cell lymphoma. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial is available at 1 location in the United States.

This trial is testing Biopsy for patients with anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (CTCL), or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 2 locations in the United States. The trial is currently recruiting patients.

This trial is testing CHT101 for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This study uses molecular subtyping to guide treatment selection for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome. The goal is to match patients to more effective therapies based on their lymphoma subtype. This trial does not currently have sites in the United States.

This trial is testing Bexarotene for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. This trial is available at 3 locations in the United States. The trial is currently recruiting patients.

This trial is testing an investigational treatment approach for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This trial is testing KK2223 for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 9 locations in the United States. The trial is not yet open for recruitment.

This trial is testing BITR2101, an experimental antibody that blocks TNFR2 for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This study is developing and validating improved flow cytometry methods to better detect circulating tumor cells in patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.

This trial is testing Ropeginterferon alfa-2b for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial is available at 1 location in the United States.

This trial is testing duvelisib (an oral PI3K inhibitor) for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. The study looks at both safety and how well the treatment controls the lymphoma. This trial is available at 1 location in the United States. The trial is not yet open for recruitment.

This trial is testing Imiquimod for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is an early Phase 1 trial, which means this is among the first tests of the treatment in patients, focusing on safety and dose. The study looks at both safety and how well the treatment controls the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.

This trial is testing Non-Interventional Study for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 10 locations in the United States. The trial is currently recruiting patients.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial is available at 7 locations in the United States.

This trial is testing an investigational treatment approach for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial is available at 1 location in the United States.

This trial is testing APR-TD011 (RLF-TD011) for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is an early Phase 1 trial, which means this is among the first tests of the treatment in patients, focusing on safety and dose. This trial is available at 1 location in the United States. The trial is not yet open for recruitment.

This trial is testing Samples collection for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.

This trial is testing allogeneic stem cell transplant (from a donor) for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. Patients are randomly assigned to different treatment groups. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.

This trial is testing Microdevices for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial is available at 1 location in the United States.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial is available at 1 location in the United States.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial is available at 3 locations in the United States.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial is available at 1 location in the United States.

This trial is testing Objective Grading of Skin Findings for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.